Core Insights - OneMedNet Corporation has announced a strategic partnership with ViuHealth to enhance its Real-World Data (RWD) offerings, particularly in the autoimmune disease sector [1][2] Group 1: Partnership Details - The partnership will integrate ViuHealth's longitudinal autoimmune disease data into OneMedNet's iRWD™ platform, which is powered by Palantir Foundry, thereby increasing the scale and diversity of regulatory-grade RWD [2][6] - ViuHealth will provide ongoing data that captures patient journeys, treatment adherence, flares, and outcomes, which will support pharmaceutical partners in drug discovery and market strategies [3][4] Group 2: Market Opportunity - The autoimmune therapeutics market is projected to exceed $166 billion globally in 2026, indicating a significant opportunity for pharmaceutical and biotechnology companies to leverage the enriched datasets for drug development and regulatory evidence [3][14] - Autoimmune diseases affect approximately 8% of the U.S. population, representing tens of millions of individuals, creating strong demand for longitudinal real-world data in life sciences and digital health [5][14] Group 3: Revenue Growth Strategy - This partnership is expected to drive OneMedNet's subscription revenue growth by integrating high-value, disease-specific data into the iRWD™ platform, making it more attractive for ongoing subscriptions rather than one-time sales [4][14] - The collaboration aims to create predictable Annual Recurring Revenue (ARR) and enhance customer retention through expanded data feeds [14] Group 4: Company Positioning - OneMedNet is positioning itself as a trusted data infrastructure provider in specialty disease areas, reinforcing its role in the rapidly growing real-world data and AI-enabled healthcare markets [7][8] - The company aims to build repeatable, subscription-oriented data partnerships that generate continuous data flows, enhancing its ability to deliver relevant cohorts reflecting real-world patient journeys [7][14]

Core Insights - OneMedNet Corporation is focused on enhancing its platform and executing its strategic plan to drive growth in 2026, highlighted by the integration of Palantir's AI platform for accelerated development [1][5][7] Financial Performance - The company reduced its total liabilities by approximately $19.6 million, achieving a 75% reduction by the end of 2025 compared to December 31, 2024 [5] - Third quarter bookings increased eightfold year-over-year from 2024 to 2025, indicating strong demand for Real-World Data (RWD) [5] Platform Development - OneMedNet is set to launch an AI-driven multimodal subscription search platform in the new year, which is expected to transform data interaction for life sciences organizations [1][5] - The iRWD™ platform integrates multiple data modalities, providing a comprehensive view of patient health and enabling real-time tracking of patient journeys [5][10] Market Trends - There is a growing demand for large-scale RWD to train, validate, and monitor AI models, alongside an increasing interest in long-term, subscription-based data relationships [5][13] - The traditional model of lengthy clinical trials is being disrupted as regulators encourage the use of Real-World Evidence (RWE) for regulatory approval and post-market surveillance [6][13] Strategic Initiatives - The company plans to expand its platform in 2026 by introducing additional services related to data cohort building and delivery, as well as solutions focused on Health Economics and Outcomes Research (HEOR) [5][13] - OneMedNet aims to address the critical bottleneck in accessing healthcare data, positioning itself to unlock the estimated $868 billion AI-driven healthcare market by 2030 [13]

Core Insights - Thermo Fisher Scientific Inc. (TMO) has initiated the enrollment of the first patient in its PPD CorEvitas Alzheimer's Disease Registry, aimed at generating real-world data for evaluating drug safety and effectiveness [1][9] - Following the announcement, TMO shares experienced a slight decline of 0.03% [2] - The CorEvitas Alzheimer's Disease Registry enhances Thermo Fisher's portfolio of clinical registries, which includes data from over 100,000 patients across more than 500 investigator sites [3] Company Overview - Thermo Fisher has a market capitalization of $213.34 billion and an earnings yield of 3.9%, significantly higher than the industry's -3.5% yield [4] - The company has consistently surpassed earnings estimates in the past four quarters, achieving an average earnings surprise of 2.9% [4] Registry Details - The registry is designed to provide a comprehensive understanding of Alzheimer's therapy outcomes, focusing on long-term safety, treatment patterns, and the disease's impact on patients [5] - It includes detailed monitoring of drug safety events, such as MRI evaluations for brain bleeding and swelling, and measures of plaque clearance [6] Industry Context - Alzheimer's disease affects an estimated 7.2 million Americans aged 65 and older, representing a significant public health challenge [7][10] - The need for rigorous evidence to guide therapeutic development and patient care is underscored by the disease's status as a leading cause of death in the United States [10] Stock Performance - Over the past year, TMO shares have increased by 8.1%, outperforming the industry growth of 1.2% [12]

RT BSCN (@BSCNews)BNB CHAIN INTEGRATES CHAINLINK DATA STANDARD TO BRING U.S. ECONOMIC DATA ONCHAIN- @BNBChain, one of the largest blockchain ecosystems with a broad global user and developer base, has adopted the @Chainlink data standard to make the U.S. Department of Commerce data available onchain.- This development introduces official economic information into the blockchain space, marking a new phase for data transparency and practical application in decentralized finance (DeFi) and prediction markets.K ...

Core Insights - OneMedNet Corporation has announced a strategic partnership with Medcase, aiming to enter the healthcare data annotation market and create a new revenue channel in the healthcare AI ecosystem [1][2][5] Market Overview - The global healthcare data annotation market is valued at $1.5 billion in 2025 and is projected to grow to $2.8 billion by 2030, indicating a significant growth phase [2] - The investment from Scale AI, amounting to $14.8 billion from Meta, has disrupted the industry, leading to an opportunity for specialized providers focused on healthcare [2] Strategic Positioning - OneMedNet will leverage Medcase's network of over 15,000 healthcare professionals to enhance its annotation services, providing regulatory-grade, de-identified Real-World Data (RWD) [3][6] - The partnership positions OneMedNet at the center of the healthcare data value chain, addressing a large unmet market need and unlocking new growth channels [5] Competitive Advantage - The combination of OneMedNet's iRWD™ platform and Medcase's annotation expertise creates a unique competitive advantage that is difficult for generalist data players to replicate [3][6] - The healthcare sector is identified as the fastest-growing and most defensible vertical within the global data annotation industry [6] Growth Potential - The demand for specialized healthcare annotation is accelerating, with a focus on meeting the unique requirements of healthcare AI developers, pharmaceutical companies, and medical technology leaders [6][7] - OneMedNet's proprietary iRWD™ platform taps into the potential of over 1,750 healthcare sites, emphasizing the importance of domain-specific data in AI model development [7]

Core Insights - OneMedNet Corporation is experiencing strong momentum in 2025, with significant achievements in expanding market presence and enhancing its AI-powered Real-World Data platform [1][2] - The company has onboarded five major data marketplaces and surpassed 121 million clinical exams in its network, indicating robust growth and demand for de-identified data [1][4] Company Highlights - **AI-Powered Platform**: OneMedNet's federated iRWD™ platform utilizes cost-effective AI tools for data search, de-identification, and curation across various industries, including healthcare, finance, telecom, and retail [4] - **Expanded Market Reach**: Partnerships with five leading data marketplaces, including Amazon Data Exchange and HealthVerity, enhance the company's position in the healthcare data ecosystem [4] - **Network Growth**: The company has established partnerships with over 1,400 healthcare provider sites, leading to an organic growth of approximately 5% annually in its medical imaging-rich RWD repository [4] - **Amplified Brand Presence**: Increased participation in industry events has resulted in over 130 qualified leads, a threefold increase from previous years, reflecting rising market interest [4] - **Diverse Customer Base**: Leading life sciences organizations license OneMedNet's regulatory-grade datasets for clinical trials and AI model development, showcasing strong market validation [4] - **Regulatory Compliance**: The datasets meet stringent FDA and international standards, facilitating real-world evidence for regulatory submissions and research [4] Industry Opportunity - The demand for Real-World Data (RWD) is increasing as traditional clinical trial models are being disrupted, with regulators encouraging the use of RWE in the approval process [5] - According to McKinsey, generative AI and RWD could unlock between $60 billion to $110 billion in annual value across the pharmaceutical and medical-device sectors, with healthcare data projected to grow at a 36% CAGR through 2030 [6] Business Model - OneMedNet has introduced a subscription-based Data License Agreement (DLA) structure to drive Annual Recurring Revenue (ARR), allowing near real-time data updates and enhancing scalability [7] Strategic Focus - The company's strategy is anchored on three pillars: Platform, Partners, and People, leveraging its AI capabilities, growing network, and experienced leadership to execute its vision [8]

Core Insights - OneMedNet has formed a strategic partnership with Protege to provide real-time access to multimodal patient data for AI developers and researchers, enhancing the development of AI solutions in healthcare [1][2][5] - The collaboration aims to improve the precision and relevance of AI models, ultimately enhancing patient outcomes and driving medical breakthroughs [2][5] - OneMedNet's data includes deep clinical information beyond traditional electronic health records, such as medical imaging and various diagnostic modalities, ensuring a comprehensive dataset for AI applications [3][7] Company Overview - OneMedNet is a leader in AI-powered Real-World Data, utilizing over 1,400 healthcare sites through its iRWD™ platform to provide valuable insights for drugmakers and medical device innovators [7] - The company focuses on delivering precision insights across various medical fields, including rare diseases, oncology, and cardiology, aiming to redefine patient care [7] - Protege serves as a platform for AI training data, facilitating compliant data exchange and supporting the creation of thoughtful AI solutions [6]

Core Insights - OneMedNet has partnered with Datavant to enhance access to tokenized, purpose-built data for life sciences and medical research, leveraging a network of 31 million patients and over 121 million clinical studies [1][2] - The integration of OneMedNet's patient tokens into Datavant's ecosystem allows for easier discovery and access to Real-World Data, improving longitudinal data visibility and connectivity for researchers [2][3] - This collaboration emphasizes OneMedNet's leadership in medical innovation through AI and robust platforms, aiming to accelerate evidence-based solutions while ensuring data privacy [3] Company Overview - OneMedNet is transforming the utilization of Real-World Data (RWD) through its iRWD™ platform, which taps into over 1,400 healthcare sites, providing insights that drive innovation in drug development and patient care [4] - The company also applies its proprietary AI to anonymize data for various industries, including finance and retail, showcasing its versatility beyond healthcare [5]

As filed with the Securities and Exchange Commission on May 6, 2024 Registration No. 333-276130 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ONEMEDNET CORPORATION (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 3721 86-2049355 (Primary Standard Industrial Classification Code Number) OneMedNet Corporation 6385 Old Shady O ...

As filed with the Securities and Exchange Commission on May 6, 2024 Registration No. 333-276130 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ONEMEDNET CORPORATION (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 3721 86-2049355 (Primary Standard Industrial Classification Code Number) OneMedNet Corporation 6385 Old Shady O ...